BlackRock Technology and Private Equity Term Trust
BTXDividend History
Investors can expect a dividend payout of $0.05 per share, scheduled to be distributed in 74 days on September 30, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 30, 2026 | $0.05 | 2026-09-15 | 2026-09-15 |
| August 31, 2026 | $0.05 | 2026-08-14 | 2026-08-14 |
| July 31, 2026 | $0.05 | 2026-07-15 | 2026-07-15 |
| June 30, 2026 | $0.05 | 2026-06-15 | 2026-06-15 |
| May 29, 2026 | $0.05 | 2026-05-15 | 2026-05-15 |
Dividends Summary
- Consistent Payer: BlackRock Technology and Private Equity Term Trust has rewarded shareholders with 21 dividend payments over the past 1 years.
- Total Returned Value: Investors who held BTX shares during this period received a total of $1.37 per share in dividend income.
- Latest Payout: The most recent dividend of $0.05/share was paid 18 days ago, on June 30, 2026.
- Yield & Schedule: BTX currently pays dividends monthly with an annual yield of 7.87%.
- Dividend Growth: Since 2025, the dividend payout has decreased by 39.5%, from $0.09 to $0.05.
- Dividend Reliability: BTX has maintained or increased its dividend for 12 consecutive payments.
Company News
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. TOP Financial Group Limited (NASDAQ: TOP) jumped 52.4% to close at $19.25. FlexShopper, Inc. (NASDAQ: FPAY) jumped 47.3% to close at $1.65 after reporting Q2 results. Timber Pha...
Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering. T2 Biosystems, Inc. (NASDAQ: TTOO) shares jumped 50.6% to $0.2379. T2 Biosystems shares jumped over 30% on Wednesday after the company on Tuesday announced it will explore the potentia...
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the N...
SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today...
SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today ...
